# About NAD Legit: An Independent NAD+ Research Digest

> NAD Legit is an independent editorial project that publishes plain-English, cited summaries of the peer-reviewed NAD+ research. Not a clinic, not a vendor, no medical advice.

An independent editorial project that reads the NAD+ literature, surfaces what it actually establishes, and cites every figure.

## What this site is

NAD Legit is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ and its precursors. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name carries a "legit" framing on purpose, and it is worth being precise about what that means. It is a *due-diligence* posture toward the literature — the question "what does the controlled human evidence actually show, and where is it overstated?" — not a claim that the site verifies, endorses, prescribes, or sells anything. NAD Legit occupies the position of a careful reader of the evidence, nothing more.

## How we read the evidence

The site is built as a transparency ledger. Every claim is tagged by how strong the evidence behind it is: findings shown in controlled human trials, findings that are preclinical only, claims that remain unproven in people, and the specific risks documented for the intravenous route. We keep three things rigorously separate that marketing tends to blur: raising a blood biomarker, changing a clinical outcome, and being an approved treatment. NAD+ clears the first bar in trials, has not cleared the second, and has not reached the third.

We also hold one accuracy line throughout: NAD+ itself and its precursors (NMN, NR) are different things, and a study of oral NMN or NR is never described as "taking NAD+." That distinction is the difference between reading the literature accurately and repeating a marketing claim.

## What we do not do

We do not recommend doses, name products to buy, or tell anyone what to take. Where we report the milligrams used in a study, that is a record of what investigators administered to participants — never guidance. NAD+ is sold as a dietary supplement and is not an FDA-approved drug; nothing here should be read as a substitute for a conversation with a qualified healthcare professional. Decisions about supplements, infusions, or any health intervention belong with a licensed clinician who knows your situation.

---

A transparency ledger of the NAD+ evidence — what the controlled trials measured, what stays unproven, and where the IV-quality risk sits — read straight from the studies, with no clinic behind the readout and nothing here dispensed, dosed, or sold.